RTTNews | Sep 21, 2020 02:16AM EDT

02:16 Monday, September 21, 2020 (RTTNews.com) - Alexion Pharmaceuticals, Inc. (ALXN) announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending marketing authorization in the European Union for a new 100 mg/mL intravenous advanced formulation of ULTOMIRIS (ravulizumab). The company noted that the European Commission typically reaches a decision on approval in approximately two months of the CHMP recommendation.

ULTOMIRIS is the first and only long-acting C5 inhibitor administered every eight weeks for the treatment of two ultra-rare diseasesparoxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Read the original article on RTTNews ( https://www.rttnews.com/3129975/alexion-pharma-chmp-adopts-positive-opinion-for-new-advanced-formulation-of-ultomiris.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved